WASHINGTON, DC (February 24, 2021) — The Association for Accessible Medicines (AAM) announced the election of its 2021 Board of Directors and Officers today.

Mr. Alok Sonig, CEO – US Generics and Global Head – Generics R&D & Biosimilars, Lupin Inc. is the 2021 AAM Chair of the Board. AAM also named Mr. Peter Hardwick, U.S. President and CEO, Apotex Corporation, Vice Chair of the Board and Mr. Brian Hoffmann, President US Generics Division, Hikma, as Treasurer.

Generic drugs saved the U.S. health system $313 billion in 2019, according to the Generic Drug Access & Savings in the U.S. report compiled by IQVIA on behalf of AAM.

The 2021 AAM Board of Directors includes:

  • Accord Healthcare, Inc.
 Jeff Hampton, President
  • American Regent
 Paul Diolosa, Senior Vice President of Operations
  • Amneal Pharmaceuticals Inc.
 Steve Manzano, Senior Vice President, General Counsel & Corporate Secretary
  • Apotex Corporation
 Peter Hardwick, President & Chief Executive Officer
  • Aurobindo Pharma USA, Inc.
 Paul McMahon, Senior Vice President Commercial Operations
  • Cipla USA
 Arunesh Verma, Chief Executive Officer
  • Dr. Reddy’s Laboratories, Inc.
 Vanessa Brill, Vice President Legal and Compliance, Americas
  • Fresenius Kabi USA
 John Ducker, President & Chief Executive Officer
  • Glenmark Pharmaceuticals, Inc. USA
 Sanjeev Krishan, President North America
  • Hikma Pharmaceuticals USA
 Brian Hoffmann, President US Generics Division
  • Jubilant Cadista
 Terrence Fullem, President
  • Kindeva Drug Delivery L.P.
 Aaron Mann, Chief Executive Officer
  • Lupin Inc.
 Alok Sonig, CEO, US Generics and Global Head Generics R&D & Biosimilars
  • Mallinckrodt Specialty Generics
 Spiro Gavaris, President, Specialty Generics
  • Mayne Pharma Group Limited
 Daniel Moore, Executive Vice President, Generic Products
  • Rhodes Pharmaceuticals L.P.
 Vincent Mancinelli II, President
  • Sagent Pharmaceuticals
 Dr. Peter Kaemmerer, Chief Executive Officer
  • Sandoz Inc., A Novartis Division
 Keren Haruvi, President, Sandoz US, Head of North America
  • Sun Pharmaceutical Industries, Inc. (together with its subsidiary Taro Pharmaceuticals USA, Inc.)
 Uday Baldota, Chief Executive Officer, Taro Pharmaceuticals
  • Teva Pharmaceuticals USA, Inc.
 George Keefe, Senior Vice President External Affairs & Public Policy
  • Zydus Pharmaceuticals USA, Inc.
 Joe Renner, Chairman

A complete list of 2021 AAM Members can be found here and learn more about each board member here.

 

MEDIA CONTACT:
Rachel Schwartz
202.249.7147 

 

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.